Austin CD, Edick MG, Ferrando RE, et al. - Given that improved lung function with lebrikizumab [anti–interleukin 13 (IL‐13) monoclonal antibody] in patients with moderate to severe uncontrolled asthma has been observed, and that lebrikizumab’s impact on eosinophilic inflammation as well as on remodelling was investigated in CLAVIER, researchers herein describe safety as well as efficacy outcomes from enrolled participants with available data from CLAVIER. Prior to as well as following 12 weeks of randomised double‐blinded treatment with lebrikizumab (n = 31) or placebo (n = 33), bronchoscopy was performed on patients suffering from uncontrolled asthma. Findings revealed that lebrikizumab did not decrease tissue eosinophil numbers. However, experts observed decreased degree of subepithelial fibrosis, a feature of airway remodelling, as well as improved lung function and decreased key pharmacodynamic biomarkers in bronchial tissues, all in correlation with lebrikizumab treatment, in pre‐specified exploratory analyses. The importance of IL‐13 in airway pathobiology was strengthened by these observations, and it was inferred that asthmatic airway remodelling may be attenuated by neutralisation of IL‐13.